

United States Hereditary Angioedema Therapeutics Market Report and Forecast 2024-2032

Market Report | 2023-11-27 | 208 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$4999.00

Report description:

United States Hereditary Angioedema Therapeutics Market Report and Forecast 2024-2032

Market Outlook

According to the report by Expert Market Research (EMR), the United States hereditary angioedema therapeutics market is projected to grow at a CAGR of 8.20% between 2024 and 2032 reaching a value of around USD 1256.28 million by 2032. Aided by the heightened awareness about the rare genetic disorder, advancements in drug development, and the push for early diagnosis, the market is expected to grow significantly by 2032.

Hereditary Angioedema is a rare, genetic disorder characterised by recurrent episodes of severe swelling (angioedema) in the skin, intestines, and airways. The swift and unpredictable onset of symptoms can often be debilitating and, in some cases, life-threatening. In the United States, the focus on HAE therapeutics has intensified in recent years, with several FDA-approved treatments entering the market.

One of the primary drivers of the United States hereditary angioedema therapeutics market growth is the heightened advocacy and awareness campaigns by organisations, patient groups, and medical professionals. These initiatives have illuminated the significance of early diagnosis and timely treatment, thus accelerating the demand for therapeutic solutions.

Parallely, the U.S. has been at the forefront of research and development in the realm of HAE therapeutics. Leading pharmaceutical companies, buoyed by grants and favourable regulations, have been channelling efforts into creating innovative drug solutions, both prophylactic and acute. The increasing number of drug approvals and the robust pipeline of drugs in clinical trials further pose a positive impact on the United States hereditary angioedema therapeutics market outlook.

Moreover, the market's expansion has been underpinned by the growing emphasis on personalised medicine. With HAE manifesting differently across patients, there is a rising demand for treatments tailored to individual patient profiles.

Consequently, biopharmaceutical firms are investing in genomics and precision medicine to design drugs that cater to specific patient subsets.

Medical advancements, however, have not been the sole driver of the United States hereditary angioedema therapeutics market demand. Technology, especially digital health platforms, has played a pivotal role in the evolution of the HAE therapeutics market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Mobile applications and telehealth services are facilitating symptom tracking, ensuring medication adherence, and fostering better patient-doctor communication, thereby enhancing the overall management of the disorder.

The United States market for hereditary angioedema therapeutics is at a significant inflection point. With the synergistic combination of medical research, technological advancements, and heightened awareness, the market is poised for substantial growth in the coming years. As more is understood about the genetic underpinnings of HAE and as drug portfolios diversify, the future looks promising for patients and stakeholders alike in the realm of HAE therapeutics.

Market Segmentation

The market can be divided based on drug type and route of administration.

Market Breakup by Drug Type

- C1-Esterase Inhibitor
- Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others

Market Breakup by Route of Administration

- Intravenous
- Subcutaneous
- Oral

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the United States hereditary angioedema therapeutics market. Some of the major players explored in the report by Expert Market Research are as follows:

- Takeda Pharmaceutical Company Limited
- BioCryst Pharmaceuticals, Inc.
- Sanofi S.A.
- CSL Behring LLC.
- Pharming Group N.V.
- Cipla Inc.
- Ionis Pharmaceuticals Inc.
- Attune Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc
- Others

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provides the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 2 Report Coverage - Key Segmentation and Scope

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 Report Description
 - 3.1 Market Definition and Outlook
 - 3.2 Properties and Applications
 - 3.3 Market Analysis
 - 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
 - 5.1 Overview
 - 5.2 Key Drivers
 - 5.3 Key Developments
 - 5.4 Competitive Structure
 - 5.5 Key Industrial Trends
- 6 Market Snapshot
- 7 Industry Opportunities and Challenges
- 8 United States Hereditary Angioedema Therapeutics Market Analysis
 - 8.1 Key Industry Highlight
 - 8.2 United States Hereditary Angioedema Therapeutics Historical Market (2018-2023)
 - 8.3 United States Hereditary Angioedema Therapeutics Market Forecast (2024-2032)
 - 8.4 United States Hereditary Angioedema Therapeutics Market by Drug Type
 - 8.4.1 C1-Esterase Inhibitor
 - 8.4.1.1 Market Share
 - 8.4.1.2 Historical Trend (2018-2023)
 - 8.4.1.3 Forecast Trend (2024-2032)
 - 8.4.2 Bradykinin B2 Receptor Antagonist
 - 8.4.2.1 Market Share
 - 8.4.2.2 Historical Trend (2018-2023)
 - 8.4.2.3 Forecast Trend (2024-2032)
 - 8.4.3 Kallikrein Inhibitor
 - 8.4.3.1 Market Share
 - 8.4.3.2 Historical Trend (2018-2023)
 - 8.4.3.3 Forecast Trend (2024-2032)
 - 8.4.4 Others
 - 8.5 United States Hereditary Angioedema Therapeutics Market by Route of Administration
 - 8.5.1 Intravenous
 - 8.5.1.1 Market Share
 - 8.5.1.2 Historical Trend (2018-2023)
 - 8.5.1.3 Forecast Trend (2024-2032)
 - 8.5.2 Subcutaneous
 - 8.5.2.1 Market Share
 - 8.5.2.2 Historical Trend (2018-2023)
 - 8.5.2.3 Forecast Trend (2024-2032)
 - 8.5.3 Oral
 - 8.5.3.1 Market Share
 - 8.5.3.2 Historical Trend (2018-2023)
 - 8.5.3.3 Forecast Trend (2024-2032)
- 9 Market Dynamics
 - 9.1 SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.1 Strengths
- 9.1.2 Weaknesses
- 9.1.3 Opportunities
- 9.1.4 Threats
- 9.2 Porter's Five Forces Analysis
 - 9.2.1 Supplier's Power
 - 9.2.2 Buyer's Power
 - 9.2.3 Threat of New Entrants
 - 9.2.4 Degree of Rivalry
 - 9.2.5 Threat of Substitutes
- 10 Competitive Landscape
 - 10.1 Market Structure
 - 10.2 Company Profiles
 - 10.2.1 Takeda Pharmaceutical Company Limited
 - 10.2.1.1 Company Overview
 - 10.2.1.2 Product Portfolio
 - 10.2.1.3 Demographic Reach and Achievements
 - 10.2.1.4 Certifications
 - 10.2.2 BioCryst Pharmaceuticals, Inc.
 - 10.2.2.1 Company Overview
 - 10.2.2.2 Product Portfolio
 - 10.2.2.3 Demographic Reach and Achievements
 - 10.2.2.4 Certifications
 - 10.2.3 Sanofi S.A.
 - 10.2.3.1 Company Overview
 - 10.2.3.2 Product Portfolio
 - 10.2.3.3 Demographic Reach and Achievements
 - 10.2.3.4 Certifications
 - 10.2.4 CSL Behring LLC.
 - 10.2.4.1 Company Overview
 - 10.2.4.2 Product Portfolio
 - 10.2.4.3 Demographic Reach and Achievements
 - 10.2.4.4 Certifications
 - 10.2.5 Pharming Group N.V.
 - 10.2.5.1 Company Overview
 - 10.2.5.2 Product Portfolio
 - 10.2.5.3 Demographic Reach and Achievements
 - 10.2.5.4 Certifications
 - 10.2.6 Cipla Inc.
 - 10.2.6.1 Company Overview
 - 10.2.6.2 Product Portfolio
 - 10.2.6.3 Demographic Reach and Achievements
 - 10.2.6.4 Certifications
 - 10.2.7 Ionis Pharmaceuticals Inc.
 - 10.2.7.1 Company Overview
 - 10.2.7.2 Product Portfolio
 - 10.2.7.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.7.4 Certifications
- 10.2.8 Attune Pharmaceuticals, Inc.
 - 10.2.8.1 Company Overview
 - 10.2.8.2 Product Portfolio
 - 10.2.8.3 Demographic Reach and Achievements
 - 10.2.8.4 Certifications
- 10.2.9 Adverum Biotechnologies, Inc.
 - 10.2.9.1 Company Overview
 - 10.2.9.2 Product Portfolio
 - 10.2.9.3 Demographic Reach and Achievements
 - 10.2.9.4 Certifications
- 10.2.10 Others
- 11 Key Trends and Developments in the Market
 - List of Figures and Tables
 - 1. United States Hereditary Angioedema Therapeutics Market: Key Industry Highlights, 2018 and 2032
 - 2. United States Hereditary Angioedema Therapeutics Historical Market: Breakup by Drug Type (USD Million), 2018-2023
 - 3. United States Hereditary Angioedema Therapeutics Market Forecast: Breakup by Drug Type (USD Million), 2024-2032
 - 4. United States Hereditary Angioedema Therapeutics Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
 - 5. United States Hereditary Angioedema Therapeutics Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
 - 6. United States Hereditary Angioedema Therapeutics Market Structure

United States Hereditary Angioedema Therapeutics Market Report and Forecast 2024-2032

Market Report | 2023-11-27 | 208 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$4999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com